<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163640</url>
  </required_header>
  <id_info>
    <org_study_id>RMA-2019-05</org_study_id>
    <nct_id>NCT04163640</nct_id>
  </id_info>
  <brief_title>Ovarian Rejuvenation for Premature Ovarian Insufficiency and Poor Ovarian Response</brief_title>
  <official_title>Ovarian Rejuvenation Through Intra-ovarian Injection of Platelet Rich Plasma for Women With Premature Ovarian Insufficiency (POI) and Poor Ovarian Response (POR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive Medicine Associates of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive Medicine Associates of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to perform a prospective randomized controlled trial seeking
      to characterize the effects of intra-ovarian injection of platelet rich plasma (PRP) on
      biomarkers of ovarian reserve as well as IVF outcomes in women with primary ovarian
      insufficiency (POI) and poor ovarian response (POR) who decline the use of an egg donor to
      establish a pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to either receive the intra-ovarian PRP injection procedure or
      not. Regardless of randomization patients will be re-assessed at the same time points for
      ovarian reserve parameters. If antral follicles are detected at follow up, patients will
      undergo controlled ovarian hyperstimulation and a routine in vitro fertilization cycle as per
      protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants with a mature oocyte retrieved- POI group</measure>
    <time_frame>24 hours post egg retrieval procedure</time_frame>
    <description>success or failure is determined by the retrieval of at least one mature oocyte</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of mature oocytes retrieved- POR group</measure>
    <time_frame>24 hours post egg retrieval procedure</time_frame>
    <description>the total number of mature oocytes retrieved</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ovarian Failure</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will receive the intra-ovarian platelet rich plasma injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to this group will not receive the intra-ovarian platelet rich plasma injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intra-ovarian platelet rich plasma injection</intervention_name>
    <description>patients will undergo a transvaginal intra-ovarian platelet rich plasma injection</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. POI according to ESHRE criteria (patient must fit both criteria):

               1. presence of menstrual disturbance defined as oligo/amenorrhea for at least 4
                  months

               2. biochemical confirmation as evidenced by an elevated FSH level &gt;25 IU/L on two
                  occasions &gt; 4 weeks apart

          2. POR defined by at least two prior cycles with POR (≤3 oocytes retrieved with a
             conventional stimulation protocol, or a cancelled cycle due to poor response)

          3. Patients declining ovum donation treatment

        Exclusion criteria

          1. Age &lt;18yo or &gt;38yrs

          2. Autoimmune or sex chromosome etiology of POI

          3. Ongoing malignancy

          4. Previous ovarian surgery

          5. Previous gonadotoxic treatment

          6. Anticoagulant use for which plasma infusion is contraindicated

          7. FMR1 mutations

          8. If the duration of the amenorrhea is more than 2 years, patients are discouraged to
             participate, although it is not an exclusion criterion.

          9. Patients with only 1 ovary

         10. BMI &gt; 35

         11. Male partner with &lt;100,000 total motile spermatozoa per ejaculate (donor sperm is
             acceptable)

         12. Surgically obtained sperm

         13. Presence of hydrosalpinges that communicate with endometrial cavity

         14. Single gene disorder or chromosomal rearrangement requiring a more detailed embryonic
             genetic analysis

         15. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness
             ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance),
             persistent endometrial fluid

         16. Use of a gestational carrier

         17. Any contraindications to undergoing in vitro fertilization or gonadotropin stimulation

         18. Known ovaries that are not accessible transvaginally.

         19. Ovarian endometrioma(s) or dermoid cyst(s) identified via transvaginal ultrasound

         20. FSH &gt; 40iu/l
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard T Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive Medicine Associates of New Jersey</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine V Whitehead, BSN, RN</last_name>
    <phone>973-656-2841</phone>
    <email>clinicalresearchteam@ivirma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Zuckerman, BS</last_name>
    <phone>973-656-2841</phone>
    <email>clinicalresearchteam@ivirma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproductive Medicine Associates of New Jersey</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine V Whitehead, BSN,RN</last_name>
      <phone>973-656-2841</phone>
      <email>clinicalresearchteam@ivirma.com</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Zuckerman, BS</last_name>
      <phone>973-656-2841</phone>
      <email>clinicalresearchteam@ivirma.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard T Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

